Antithrombotic or anti-platelet agents in patients undergoing permanent pacemaker implantation

Korean Circulation Journal

Volumn 42, Issue 8, 2012, Pages 538-542

  Lee, Chang Kun ^a   Yoo, Sang Yong ^a   Hong, Man Yong ^a   Jang, Jin Kun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Aspirin; Clopidogrel; Hematoma; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRIDGING THERAPY; CARDIOVASCULAR DISEASE; FEMALE; HEMATOMA; HEMOSTASIS; HEPARINIZATION; HOSPITALIZATION; HUMAN; IMPLANTED HEART PACEMAKER; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT;

EID: 84866536796     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2012.42.8.538     Document Type: Article

References (24)

1. Gupta A, Halleran SM, Krishnan K, Trohman RG. Rescue permanent iliac vein pacing after epicardial lead failure: an unusual reversal of pacing fortune. Europace 2008;10:1236-8.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
3. Lee GY, Chang BS, Song JU, et al. Deglutition syncope associated with ventricular asystole in a patient with permanent atrial fibrillation. Korean Circ J 2010;40:99-101.
4. Lee CK, Shin DH, Jang JK, et al. Progressive familial heart block type I in a Korean patient Korean Circ J 2011;41:276-9.
5. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-207.
6. Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004;27:358-60.
7. Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
8. Möllmann H, Nef HM, Hamm CW, Elss̈sser A How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol 2009;98:8-15.
9. Llau JV, Lopez-Forte C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesthesbl 2009;26:181-7.
10. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000;57:1710-3.
11. Marquie C, De Geeter G, Klug D, et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006;8:283-7.
12. Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol 1998;21:1730-4.
13. Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745-9.
14. Cheng A, Nazarian S, Brinker JA, et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm 2011;8:536-40.
15. Daubert JC, Mabo P. Continue or withhold oral anticoagulation in high-risk patients undergoing pacemaker or ICD implantation. Eur Heart J 2009.
16. Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest 2004;126:1177-86.
17. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhythmia device implantation safe under dual antiplatelet therapy? Pacing Clin Electrophysiol 2010;33:394-9.
18. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3:312-8.
19. Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55:2376-82.
20. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119:1634-42.
21. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49.
22. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8.
23. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):S8-21.
24. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007;49:734-9.